Disease-Free Survival
Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial
Roche; giredestrant; breast cancer; hormone receptor-positive; ER-positive; HER2-negative; oral SERD; endocrine therapy; adjuvant therapy; recurrence risk; phase III lidERA trial; disease-free survival; San Antonio Breast Cancer Symposium
Roche’s Oral SERD Giredestrant Delays Early Breast Cancer Recurrence in Late-Stage Trial
Roche; oral SERD; giredestrant; Phase 3 trial; early breast cancer; ER-positive; HER2-negative; disease-free survival; adjuvant therapy; recurrence prevention
Merck & Co.’s Welireg Notches Wins in Kidney Cancer Combo Studies
Welireg; kidney cancer; renal cell carcinoma; Keytruda; Lenvima; adjuvant setting; combination therapy; Phase 3 trials; progression-free survival; disease-free survival
Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025
Tecentriq; atezolizumab; ctDNA-guided therapy; IMvigor011; bladder cancer; muscle-invasive bladder cancer; adjuvant treatment; overall survival; disease-free survival; ESMO 2025; Signatera; Genentech; Roche
AstraZeneca’s Imfinzi Achieves Success in Bladder Cancer Trial, Falls Short in Lung Cancer Study
AstraZeneca, Imfinzi, bladder cancer, lung cancer, Phase III trials, disease-free survival